With the plasmid DNA manufacturing market set to rise to $39.3Bn by 2033, and the demand for advanced therapies continuing to surge as gene therapy reaches new heights and DNA vaccines promise to transform outbreak response, there has never been a more crucial time to revolutionize the production of high-quality DNA as a starting material and API.

The 2nd DNA Process Development & Manufacturing Summit 2025 returned as the world’s only industry-dedicated technical forum focused on optimizing process development for plasmid and cell-free DNA, adhering to regulatory requirements to streamline IND approvals for advanced therapies, and developing scalable, efficient manufacturing solutions.

Industry experts from the likes of Pfizer, Sanofi, Novartis, Beam Therapeutics, Moderna, Merck and Chroma Medicine united to share innovations in plasmid design, advances off-the-shelf lysis equipment and purification techniques, and strategies to support timely, cost-efficient large-scale DNA production.